One and done: new study tests Single-Visit radiation for bone metastases
NCT ID NCT07202273
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This study tests whether a single, quick radiation session can treat painful bone metastases without the usual planning visit. About 40 adults with cancer and one or two painful bone spots will get one dose of radiation in a single trip to the hospital. The goal is to see if this simpler approach is feasible and can improve quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- radiation therapy
- What this could lead to
- If it works, this could make palliative radiation for bone pain much faster and more convenient, requiring only one hospital visit.
- What could go wrong
- This is a small, early feasibility study with only 40 people. It may not work for all types of bone metastases, and there is a risk the single session might not control pain as well as standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant aged ≥ 18 years. * Diagnosis of any cancer with one to two sites of painful and treatable metastatic bone lesions. * Bone metastases are causing pain or instability in the opinion of the treating investigator. * Amenable to single fraction radiation therapy per the discretion of the treating physician. * CT collected within 60 days of registration with adequate visualization of target site as determined by the treating investigator. * ECOG Performance Status ≤ 2. * Participants must adhere to the following sex and contraceptive/barrier requirements: * If participant is of childbearing potential, they must have a negative pregnancy test ≤ 14 days before the planned date of radiation therapy. This may be completed on the day of radiation if results from the pregnancy test are available for review before treatment. * For participants of non-child bearing potential: The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply: * \< 50 years of age: * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution ---≥ 50 years of age: * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or * Had radiation-induced menopause with last menses \>1 year ago; or * Had chemotherapy-induced menopause with last menses \>1 year ago * Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception. * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines. Exclusion Criteria: * Evidence of spinal cord compression caused by the bone metastases to be treated. * Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures. * Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study. * Participants taking prohibited medications as described in Section 6.7.1.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bone metastases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Huntsman Cancer Institute/University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can radiation boost a personalized prostate cancer vaccine?
- Preventive radiation may stop bone events before they start — a trial puts it to the test
- Can a new capsule ease bone metastasis pain without opioids?
- Hip muscle repair method may improve walking after bone cancer surgery
- New model aims to predict jaw bone disease before it strikes
- Could removing the primary tumor boost survival in stage IV breast cancer with Bone-Only spread?